References
- Sun W, Xing Y, Zhou F, et al. Association analysis of triglyceride glucose-body mass index and bone turnover markers in patients with type 2 diabetes mellitus. Diabetes Metabol Syndrome Obes. 2023;16:1435–1447. doi:10.2147/DMSO.S406849
- Greenhill C. Shared variants for osteoporosis and T2DM. Nat Rev Endocrinol. 2018;14(11):627. doi:10.1038/s41574-018-0095-0
- Cruz-Jentoft AJ, Sayer AA. Sarcopenia. Lancet. 2019;393(10191):2636–2646. doi:10.1016/S0140-6736(19)31138-9
- DeFronzo RA, Norton L, Abdul-Ghani M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol. 2017;13(1):11–26. doi:10.1038/nrneph.2016.170
- Horiuchi N, Maeda T. Statins and bone metabolism. Oral Dis. 2006;12(2):85–101. doi:10.1111/j.1601-0825.2005.01172.x